Rebamipide is a cytoprotector developed in Japan, where it has been successfully used to treat stomach diseases for 30 years. The initially discovered mechanisms of action of the drug included the induction of prostaglandins and the removal of free oxygen radicals. Over the past 10 years, studies have been conducted that have discovered new therapeutic targets for the drug, its new dosage forms have been developed, which has made it possible to use rebamipide to treat diseases such as NSAID enteropathy, ulcerative colitis, radiation colitis, reservoirs, enteropathy with impaired membrane digestion. It is used in endoscopy, ophthalmology, chemotherapy, rheumatology.

rebamipide, cytoprotector, enteropathy, disaccharidases, peptic ulcer, ulcerative colitis, radiation colitis.

Takano H, Uchida S, Kashiwagura Y, et al. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability. Chem Pharm Bull. 2019;67(2):112-9. doi: 10.1248/cpb.c18-00629

Kim KT, Lee JY, Park JH, et al. Capmul MCM/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide. J Nanosci Nanotechnol. 2017 Apr;17(4):2340-344. doi:10.1166/jnn.2017.13314

Hasegawa S, Sekino H, Matsuoka O, et al. Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers. Clin Drug Investig. 2003;23:771-9. doi: 10.2165/00044011-200323120-00002

Naito Y, Yoshikawa T. Rebamipide: A gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi: 10.1586/egh.10.25